AVNS — Avanos Medical, Inc.

Avanos Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Net Sales: Approximately $178 million, with organic sales for strategic segments up 10% year-over-year.
• Adjusted EPS: $0.22, with a full-year estimate raised to $0.85 - $0.95 per share.
• Adjusted EBITDA: $20 million, with an adjusted gross margin of 52.8%.
• SG&A as a Percentage of Revenue: 40.6%.
• Free Cash Flow: $7 million for the quarter, with an annual estimate of $25 million - $30 million, inclusive of one-time charges.

2. Strategic Updates and Business Highlights:

• Strong growth in the Specialty Nutrition Systems (SNS) segment, achieving 14.5% organic growth, driven by robust demand for enteral feeding products.
• The Pain Management and Recovery segment saw normalized organic sales growth of 2.4%, led by double-digit growth in the radiofrequency ablation business.
• Successful divestiture of the hyaluronic acid business and acquisition of Nexus Medical, expected to enhance revenue and profitability in the neonatal and pediatric markets.
• Implementation of cost improvement initiatives projected to yield $15 million - $20 million in annualized savings by the end of 2026.

3. Forward Guidance and Outlook:

• Full-year revenue estimates raised to $690 million - $700 million, reflecting strong sales momentum and the impact of acquisitions.
• Anticipation of lower growth in the SNS segment in Q4 due to normalization of inventory levels and one-off tailwinds from the previous year.
• Continued focus on mitigating tariff impacts, with expected costs of approximately $18 million related to tariffs in 2026.

4. Bad News, Challenges, or Points of Concern:

• The ongoing tariff environment is expected to continue impacting gross margins and overall profitability into 2026.
• The Game Ready product line showed a decline in revenue year-over-year, although it maintained similar levels to the first two quarters of 2025.
• The surgical pain business remained flat, with delays in the implementation of the NOPAIN Act affecting growth.

5. Notable Q&A Insights:

• Management emphasized a streamlined R&D approach, adopting a hybrid model for product development to enhance speed to market.
• There is an appetite for further M&A, particularly in the SNS space, with management actively seeking synergistic opportunities.
• Clarification on free cash flow guidance confirmed it includes the impact of tariffs and one-time charges from transformation efforts.

Overall, Avanos reported a strong quarter with strategic growth initiatives and a focus on operational efficiency, despite facing challenges from tariffs and specific product line declines.